IXAKA
DEAD

Serial Number

90557587

Owner

Ixaka Limited

Attorney

Kevin S. Costanza

Filing Date

Mar 3, 2021

Add to watchlist:

No watchlists yet
View on USPTO

IXAKA Trademark

Serial Number: 90557587

IXAKA is a trademark filed by Ixaka Limited on March 3, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Ixaka Limited (2 trademarks)

London SW1X0BD , GB

Entity Type: 99

Trademark Details

Filing Date

March 3, 2021

Registration Date

Not Registered

Published for Opposition

June 7, 2022

Goods & Services

Chemicals for use in science, scientific research and for laboratory use; analytical and diagnostic reagents for in vitro use for scientific or research use

Drug delivery devices sold empty, namely, syringes, bags, infusion and injection sets; structural parts, fittings and accessories for all the aforesaid goods

Production of cell lines for use in the manufacture of biopharmaceuticals; Protein fabrication, production, and manufacture for others; Custom manufacture of pharmaceuticals by pharmaceutical compounders; custom manufacture of biopharmaceuticals by pharmaceutical compounders

Chemical, analytical and diagnostic reagents for in vivo use for medical purposes; Pharmaceutical preparations for use in the prevention and treatment of cardiovascular diseases, cancer and genetic disorders; Pharmaceutical preparations for the treatment of ophthalmic diseases and conditions, and for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders

Scientific, medical and industrial research and development services in the field of cardiovascular diseases, cancer, genetic disorders, ophthalmic diseases and conditions, inflammation and inflammatory diseases and disorders and metabolic diseases and disorders; clinical research in the field of cardiovascular diseases, cancer and genetic disorders, ophthalmic diseases and conditions, inflammation and inflammatory diseases and disorders and metabolic diseases and disorders; laboratory research in the field of cardiovascular diseases, cancer and genetic disorders, ophthalmic diseases and conditions, inflammation and inflammatory diseases and disorders and metabolic diseases and disorders; research and development of new drugs and clinical products; materials analyzing; chemical analysis; scientific laboratory services; laboratory testing services for scientific research purposes; medical laboratory services; information and advisory services relating to the foregoing, including such services provided on-line from a computer network or the Internet; Research and development services for pharmaceuticals and for the treatment of diseases and injuries; Genetic engineering services for scientific research purposes; Genetic research being scientific research; genetic testing for scientific research purposes; medical and pharmacological research services; research and development in the fields of biotechnology, biopharmaceuticals and gene therapy; medical and scientific research, namely, conducting clinical trials for others; Research and development of pharmaceutical preparations

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 4, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 4, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 4, 2023 EXRA
SOU EXTENSION 2 GRANTED
Aug 2, 2023 EX2G
SOU EXTENSION 2 FILED
Aug 2, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 2, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 14, 2022 EXRA
SOU EXTENSION 1 GRANTED
Dec 12, 2022 EX1G
SOU EXTENSION 1 FILED
Dec 12, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 12, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 2, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 7, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 7, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 18, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 30, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 27, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 27, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 27, 2022 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Apr 18, 2022 GPRN
PRIORITY ACTION E-MAILED
Apr 18, 2022 GPRA
PRIORITY ACTION WRITTEN
Apr 18, 2022 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 28, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 28, 2022 CRFA
ASSIGNED TO LIE
Mar 26, 2022 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 23, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 26, 2021 GNRN
NON-FINAL ACTION E-MAILED
Sep 26, 2021 GNRT
NON-FINAL ACTION WRITTEN
Sep 26, 2021 CNRT
ASSIGNED TO EXAMINER
Sep 25, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 2, 2021 NWOS
NEW APPLICATION ENTERED
Mar 6, 2021 NWAP